Cancer Prevention II - 6 Angebote vergleichen
| Preise | 2013 | 2014 | 2015 | 2017 | 2021 |
|---|---|---|---|---|---|
| Schnitt | € 116,45 | € 101,85 | € 99,74 | € 223,63 | € 182,99 |
| Nachfrage |
1
Cancer Prevention II
DE HC NWISBN: 9783540692966 bzw. 3540692967, in Deutsch, Springer, Berlin, gebundenes Buch, neu.
Lieferung aus: Deutschland, 免費送貨.
Von Händler/Antiquariat, buecher.de GmbH & Co. KG, [1].
More than 180 participants and experts from 31 countries met for the fifth time in 10 years in St. Gallen, Switzerland for a 3-day conference to discuss important current issues of clinical cancer prevention. The meeting was again organized and co-sponsored by St. Gallen Oncology Conferences (SONK). While SONK has been extremely successful in organizing large international c- gresses on "Primary Therapy of Early Breast CancerâEUR as well as "Supportive Care in CancerâEUR for more than 20 years, the idea of promoting interdisciplinary, clinically oriented meetings on cancer prevention is a more recent and not yet generally accepted and w- comed concept in modern oncology. Since todayâs medical expenses are soaring and me- cal research budgets are stagnating or even being cut, neither politicians nor industry is willing to risk an additional unpredictable channel of expenses, such as that demanded by clinical cancer prevention efforts! In SwitzerlandâEUR"and we fear in many other parts of the globeâEUR"some 97%-98% or even a greater percentage of health budgets is spent for curative and palliative/rehabilitative m- icine. Since a meager 2%-3% of national health budgets is for preventive medicine, even less than that proportion is specifically allocated for cancer prevention. When the money for "curing and caringâEUR for the diseased populace runs short, there is likely not much left for partly controversial disease prevention in the (still) healthy part of the population. 2008. xx, 252 S. w. figs. (some col.). Sofort lieferbar, Hardcover, Neuware.
Von Händler/Antiquariat, buecher.de GmbH & Co. KG, [1].
More than 180 participants and experts from 31 countries met for the fifth time in 10 years in St. Gallen, Switzerland for a 3-day conference to discuss important current issues of clinical cancer prevention. The meeting was again organized and co-sponsored by St. Gallen Oncology Conferences (SONK). While SONK has been extremely successful in organizing large international c- gresses on "Primary Therapy of Early Breast CancerâEUR as well as "Supportive Care in CancerâEUR for more than 20 years, the idea of promoting interdisciplinary, clinically oriented meetings on cancer prevention is a more recent and not yet generally accepted and w- comed concept in modern oncology. Since todayâs medical expenses are soaring and me- cal research budgets are stagnating or even being cut, neither politicians nor industry is willing to risk an additional unpredictable channel of expenses, such as that demanded by clinical cancer prevention efforts! In SwitzerlandâEUR"and we fear in many other parts of the globeâEUR"some 97%-98% or even a greater percentage of health budgets is spent for curative and palliative/rehabilitative m- icine. Since a meager 2%-3% of national health budgets is for preventive medicine, even less than that proportion is specifically allocated for cancer prevention. When the money for "curing and caringâEUR for the diseased populace runs short, there is likely not much left for partly controversial disease prevention in the (still) healthy part of the population. 2008. xx, 252 S. w. figs. (some col.). Sofort lieferbar, Hardcover, Neuware.
2
Cancer Prevention II (2008)
~EN NWISBN: 9783540692966 bzw. 3540692967, vermutlich in Englisch, Springer Berlin, neu.
Lieferung aus: Deutschland, Sofort lieferbar.
More than 180 participants and experts from 31 countries met for the fifth time in 10 years in St. Gallen, Switzerland for a 3-day conference to discuss important current issues of clinical cancer prevention. The meeting was again organized and co-sponsored by St. Gallen Oncology Conferences (SONK). While SONK has been extremely successful in organizing large international c- gresses on “Primary Therapy of Early Breast Cancer” as well as “Supportive Care in Cancer” for more than 20 years, the idea of promoting interdisciplinary, clinically oriented meetings on cancer prevention is a more recent and not yet generally accepted and w- comed concept in modern oncology. Since today’s medical expenses are soaring and me- cal research budgets are stagnating or even being cut, neither politicians nor industry is willing to risk an additional unpredictable channel of expenses, such as that demanded by clinical cancer prevention efforts! In Switzerland—and we fear in many other parts of the globe—some 97%–98% or even a greater percentage of health budgets is spent for curative and palliative/rehabilitative m- icine. Since a meager 2%–3% of national health budgets is for preventive medicine, even less than that proportion is specifically allocated for cancer prevention. When the money for “curing and caring” for the diseased populace runs short, there is likely not much left for partly controversial disease prevention in the (still) healthy part of the population. gebundene Ausgabe, 10.12.2008.
More than 180 participants and experts from 31 countries met for the fifth time in 10 years in St. Gallen, Switzerland for a 3-day conference to discuss important current issues of clinical cancer prevention. The meeting was again organized and co-sponsored by St. Gallen Oncology Conferences (SONK). While SONK has been extremely successful in organizing large international c- gresses on “Primary Therapy of Early Breast Cancer” as well as “Supportive Care in Cancer” for more than 20 years, the idea of promoting interdisciplinary, clinically oriented meetings on cancer prevention is a more recent and not yet generally accepted and w- comed concept in modern oncology. Since today’s medical expenses are soaring and me- cal research budgets are stagnating or even being cut, neither politicians nor industry is willing to risk an additional unpredictable channel of expenses, such as that demanded by clinical cancer prevention efforts! In Switzerland—and we fear in many other parts of the globe—some 97%–98% or even a greater percentage of health budgets is spent for curative and palliative/rehabilitative m- icine. Since a meager 2%–3% of national health budgets is for preventive medicine, even less than that proportion is specifically allocated for cancer prevention. When the money for “curing and caring” for the diseased populace runs short, there is likely not much left for partly controversial disease prevention in the (still) healthy part of the population. gebundene Ausgabe, 10.12.2008.
3
Cancer Prevention II
DE NWISBN: 9783540692966 bzw. 3540692967, in Deutsch, Springer-Verlag GmbH, neu.
Lieferung aus: Deutschland, 免費送貨.
Von Händler/Antiquariat, Rheinberg-Buch, [3813847].
Neuware - More than 180 participants and experts from 31 countries met for the fifth time in 10 years in St. Gallen, Switzerland for a 3-day conference to discuss important current issues of clinical cancer prevention. The meeting was again organized and co-sponsored by St. Gallen Oncology Conferences (SONK). While SONK has been extremely successful in organizing large international c- gresses on 'Primary Therapy of Early Breast Cancer' as well as 'Supportive Care in Cancer' for more than 20 years, the idea of promoting interdisciplinary, clinically oriented meetings on cancer prevention is a more recent and not yet generally accepted and w- comed concept in modern oncology. Since today's medical expenses are soaring and me- cal research budgets are stagnating or even being cut, neither politicians nor industry is willing to risk an additional unpredictable channel of expenses, such as that demanded by clinical cancer prevention efforts! In Switzerland-and we fear in many other parts of the globe-some 97%-98% or even a greater percentage of health budgets is spent for curative and palliative/rehabilitative m- icine. Since a meager 2%-3% of national health budgets is for preventive medicine, even less than that proportion is specifically allocated for cancer prevention. When the money for 'curing and caring' for the diseased populace runs short, there is likely not much left for partly controversial disease prevention in the (still) healthy part of the population. Buch, Neuware, 242x164x20 mm, 578g.
Von Händler/Antiquariat, Rheinberg-Buch, [3813847].
Neuware - More than 180 participants and experts from 31 countries met for the fifth time in 10 years in St. Gallen, Switzerland for a 3-day conference to discuss important current issues of clinical cancer prevention. The meeting was again organized and co-sponsored by St. Gallen Oncology Conferences (SONK). While SONK has been extremely successful in organizing large international c- gresses on 'Primary Therapy of Early Breast Cancer' as well as 'Supportive Care in Cancer' for more than 20 years, the idea of promoting interdisciplinary, clinically oriented meetings on cancer prevention is a more recent and not yet generally accepted and w- comed concept in modern oncology. Since today's medical expenses are soaring and me- cal research budgets are stagnating or even being cut, neither politicians nor industry is willing to risk an additional unpredictable channel of expenses, such as that demanded by clinical cancer prevention efforts! In Switzerland-and we fear in many other parts of the globe-some 97%-98% or even a greater percentage of health budgets is spent for curative and palliative/rehabilitative m- icine. Since a meager 2%-3% of national health budgets is for preventive medicine, even less than that proportion is specifically allocated for cancer prevention. When the money for 'curing and caring' for the diseased populace runs short, there is likely not much left for partly controversial disease prevention in the (still) healthy part of the population. Buch, Neuware, 242x164x20 mm, 578g.
4
Cancer Prevention II
DE NWISBN: 9783540692966 bzw. 3540692967, in Deutsch, Springer-Verlag GmbH, neu.
Lieferung aus: Deutschland, 免費送貨.
Von Händler/Antiquariat, Buchhandlung Hoffmann, [3174608].
Neuware - More than 180 participants and experts from 31 countries met for the fifth time in 10 years in St. Gallen, Switzerland for a 3-day conference to discuss important current issues of clinical cancer prevention. The meeting was again organized and co-sponsored by St. Gallen Oncology Conferences (SONK). While SONK has been extremely successful in organizing large international c- gresses on 'Primary Therapy of Early Breast Cancer' as well as 'Supportive Care in Cancer' for more than 20 years, the idea of promoting interdisciplinary, clinically oriented meetings on cancer prevention is a more recent and not yet generally accepted and w- comed concept in modern oncology. Since today's medical expenses are soaring and me- cal research budgets are stagnating or even being cut, neither politicians nor industry is willing to risk an additional unpredictable channel of expenses, such as that demanded by clinical cancer prevention efforts! In Switzerland-and we fear in many other parts of the globe-some 97%-98% or even a greater percentage of health budgets is spent for curative and palliative/rehabilitative m- icine. Since a meager 2%-3% of national health budgets is for preventive medicine, even less than that proportion is specifically allocated for cancer prevention. When the money for 'curing and caring' for the diseased populace runs short, there is likely not much left for partly controversial disease prevention in the (still) healthy part of the population. Buch, Neuware, 242x164x20 mm, 578g.
Von Händler/Antiquariat, Buchhandlung Hoffmann, [3174608].
Neuware - More than 180 participants and experts from 31 countries met for the fifth time in 10 years in St. Gallen, Switzerland for a 3-day conference to discuss important current issues of clinical cancer prevention. The meeting was again organized and co-sponsored by St. Gallen Oncology Conferences (SONK). While SONK has been extremely successful in organizing large international c- gresses on 'Primary Therapy of Early Breast Cancer' as well as 'Supportive Care in Cancer' for more than 20 years, the idea of promoting interdisciplinary, clinically oriented meetings on cancer prevention is a more recent and not yet generally accepted and w- comed concept in modern oncology. Since today's medical expenses are soaring and me- cal research budgets are stagnating or even being cut, neither politicians nor industry is willing to risk an additional unpredictable channel of expenses, such as that demanded by clinical cancer prevention efforts! In Switzerland-and we fear in many other parts of the globe-some 97%-98% or even a greater percentage of health budgets is spent for curative and palliative/rehabilitative m- icine. Since a meager 2%-3% of national health budgets is for preventive medicine, even less than that proportion is specifically allocated for cancer prevention. When the money for 'curing and caring' for the diseased populace runs short, there is likely not much left for partly controversial disease prevention in the (still) healthy part of the population. Buch, Neuware, 242x164x20 mm, 578g.
5
Cancer Prevention: No. 2 (Hardback) (2008)
DE HC NWISBN: 9783540692966 bzw. 3540692967, in Deutsch, Springer-Verlag Berlin and Heidelberg GmbH Co. KG, Germany, gebundenes Buch, neu.
Lieferung aus: Deutschland, Versandkostenfrei.
Von Händler/Antiquariat, The Book Depository EURO [60485773], Slough, United Kingdom.
Language: English Brand New Book. More than 180 participants and experts from 31 countries met for the fifth time in 10 years in St. Gallen, Switzerland for a 3-day conference to discuss important current issues of clinical cancer prevention. The meeting was again organized and co-sponsored by St. Gallen Oncology Conferences (SONK). While SONK has been extremely successful in organizing large international c- gresses on Primary Therapy of Early Breast Cancer as well as Supportive Care in Cancer for more than 20 years, the idea of promoting interdisciplinary, clinically oriented meetings on cancer prevention is a more recent and not yet generally accepted and w- comed concept in modern oncology. Since today s medical expenses are soaring and me- cal research budgets are stagnating or even being cut, neither politicians nor industry is willing to risk an additional unpredictable channel of expenses, such as that demanded by clinical cancer prevention efforts! In Switzerland-and we fear in many other parts of the globe-some 97 -98 or even a greater percentage of health budgets is spent for curative and palliative/rehabilitative m- icine. Since a meager 2 -3 of national health budgets is for preventive medicine, even less than that proportion is specifically allocated for cancer prevention. When the money for curing and caring for the diseased populace runs short, there is likely not much left for partly controversial disease prevention in the (still) healthy part of the population.
Von Händler/Antiquariat, The Book Depository EURO [60485773], Slough, United Kingdom.
Language: English Brand New Book. More than 180 participants and experts from 31 countries met for the fifth time in 10 years in St. Gallen, Switzerland for a 3-day conference to discuss important current issues of clinical cancer prevention. The meeting was again organized and co-sponsored by St. Gallen Oncology Conferences (SONK). While SONK has been extremely successful in organizing large international c- gresses on Primary Therapy of Early Breast Cancer as well as Supportive Care in Cancer for more than 20 years, the idea of promoting interdisciplinary, clinically oriented meetings on cancer prevention is a more recent and not yet generally accepted and w- comed concept in modern oncology. Since today s medical expenses are soaring and me- cal research budgets are stagnating or even being cut, neither politicians nor industry is willing to risk an additional unpredictable channel of expenses, such as that demanded by clinical cancer prevention efforts! In Switzerland-and we fear in many other parts of the globe-some 97 -98 or even a greater percentage of health budgets is spent for curative and palliative/rehabilitative m- icine. Since a meager 2 -3 of national health budgets is for preventive medicine, even less than that proportion is specifically allocated for cancer prevention. When the money for curing and caring for the diseased populace runs short, there is likely not much left for partly controversial disease prevention in the (still) healthy part of the population.
Lade…